A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
There is need for improved human influenza vaccines, particularly for older adults who are at greatest risk for severe disease, as well as to address the continuous antigenic drift within circulating human subtypes of influenza virus. We have engineered an influenza virus-like particle (VLP) as a new generation vaccine candidate purified from the supernatants of Sf9 insect cells following infection by recombinant baculoviruses to express three influenza virus proteins, hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1). In this study, a seasonal trivalent VLP vaccine (TVV) formulation, composed of influenza A H1N1 and H3N2 and influenza B VLPs, was evaluated in mice and ferrets for the ability to elicit antigen-specific immune responses. Animals vaccinated with the TVV formulation had hemagglutination-inhibition (HAI) antibody titers against all three homologous influenza virus strains, as well as HAI antibodies against a panel of heterologous influenza viruses. HAI titers elicited by the TVV were statistically similar to HAI titers elicited in animals vaccinated with the corresponding monovalent VLP. Mice vaccinated with the TVV had higher level of influenza specific CD8+ T cell responses than a commercial trivalent inactivated vaccine (TIV). Ferrets vaccinated with the highest dose of the VLP vaccine and then challenged with the homologous H3N2 virus had the lowest titers of replicating virus in nasal washes and showed no signs of disease. Overall, a trivalent VLP vaccine elicits a broad array of immunity and can protect against influenza virus challenge.
Ross
Ted M
TM
Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. tmr15@pitt.edu
Mahmood
Kutub
K
Crevar
Corey J
CJ
Schneider-Ohrum
Kirsten
K
Heaton
Penny M
PM
Bright
Rick A
RA
D000818:Animals; D005260:Female; D005289:Ferrets / Q000276:immunology*; D005818:Genetic Engineering / Q000379:methods; D006386:Hemagglutination Tests; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D009981:Influenza B virus / Q000276:immunology; D008297:Male; D051379:Mice; D009975:Orthomyxoviridae / Q000276:immunology*; D012621:Seasons; D013045:Species Specificity; D015164:Vaccines, Inactivated / Q000276:immunology; D058425:Vaccines, Virus-Like Particle / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics
D015164:Vaccines, Inactivated; D058425:Vaccines, Virus-Like Particle; D014764:Viral Proteins